Agilent Technologies, Inc. · NYSE:A
Agilent Technologies — Q4 2023 Earnings Presentation
10 slides from Agilent Technologies's earnings presentation, Nov 20, 2023
Slide 1: Agilent Technologies Q4'23 Financial Results Overview
Agilent Technologies Q4’23 Financial Results Overview
Slide 2: Safe Harbor
Safe Harbor These presentations contain forward-looking statements (including, without limitation, information, and future guidance on the company’s goals, priorities, revenue, revenue growth, earnings per share, operating margin, operating cash flow, capital expenditures, capital allocation, growth
Slide 3: Agilent Results FY'23
Agilent Results FY’23 A leading lab partner with unsurpassed capabilities and scale FY’23 Financial Metrics FY’23 Highlights • Revenues: $6.83B, -0.2% reported, • Growth: Delivered core growth in a challenging market environment, +1.5% y/y core(1)(2) (-1.8% FX,+0.1% M&A). completing a 4-year period
Slide 4: Agilent Results Q4'23
Agilent Results Q4’23 Q4’23 Financial Metrics Q4’23 Highlights • Revenues: $1.69B, -8.7% reported, • Growth: Revenue declined driven by lower demand for instrumentation, -9.7% y/y core(1)(2) (+1.1% FX,-0.1% M&A). particularly in China and the Pharma end market, partially offset by Services and key g
Slide 5: Q4 FY'23 Core Growth Results by End Market
Q4 FY’23 Core Growth(2) Results by End Market Delivering on areas of opportunity across our end markets despite challenging macro conditions Pharma: Down -14% with +7% BioPharma growth ex-China led by service and consumables, offset by weakness in China and dampened instrument spending. Chemical
Slide 6: Life Sciences & Applied Markets Group (LSAG)
Life Sciences & Applied Markets Group (LSAG) Instrumentation, Informatics, and • LSAG closes FY23 with a 4-year CAGR of 7%, as our Consumables instrument platforms continue to deliver the innovation, for Analytical Laboratories quality and ease-of-use that make a difference for customers. • Increasi
Slide 7: Agilent CrossLab Group (ACG)
Agilent CrossLab Group (ACG) Analytical Laboratory • CrossLab delivered another solid quarter in Services Q4, growing +4% with continued double- digit growth in service contracts. • Delivered growth in every end market and all regions except China during the quarter. • Customer satisfaction scores r
Slide 8: Diagnostics and Genomics Group (DGG)
Diagnostics and Genomics Group (DGG) Pathology, Genomics, and Nucleic Acid Manufacturing • FY23 growth of 3% was led by another strong double-digit growth performance from our GMP- grade oligonucleotide manufacturing business, as well as high-single digit growth in our Clinical Pathology franchise.
Slide 9: Q1'24 and FY'24 Guidance and Forward-looking Considerations
Q1’24 and FY’24 Guidance and Forward-looking Considerations Based on Forecasted Currency Exchange Rates Q1’24 Guidance (1) FY’24 Guidance (1) Low End High End Low End High End Net Revenue ($M) $1,555 $1,605 Net Revenue ($M) $6,710 $6,810 Y/Y Core Revenue Growth (2) -11.3% -8.5% Y/Y Core Revenue Grow
Slide 10: Q4'23 Financial Results Overview
11/20/2023 Q4'23 Financial Results Overview